Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single-center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) Disease and Typhoid Fever, Including Dose and Schedule Finding in Infants, in Africa

NCT07286370 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07286370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07286370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Observer-Blind, Randomized, Controlled, Age-De-Escalation, Single-center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella (iNTS) Disease and Typhoid Fever, Including Dose and Schedule Finding in Infants, in Africa
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Recruiting
Start date
April 1, 2026
Completion date
April 27, 2028
Enrollment
537 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

salmonella infections